This review focuses on searching evidence that supports that polyunsaturated fatty acid supplementation (PUFA N-3) will induce specialized pro-resolving lipidmediators (SPMs) which will be responsible could aid in the resolution of vascular inflammation. Usingthe Cochrane method, a bibliographic search was carried out in on line databases, such as PubMed, Cochrane Library, LILACS, Mediagraphic and Nietoeditores, all studies about the role of PUFA N-3 in the treatment ofcardiovascular diseases were reviewed, in English or Spanish. The selection of the studies was carried out independently, by two reviewers, randomized clinical trials (RCTs) were selected until April 10, 2019, data from each study were extracted and the quality of these studies was evaluated with the Cochrane Bias Risk Tool. A total of 606 studies were initially retrieved, 199 were duplicates and finally 6 RCT studies met the criteria inclusion to be included in this systematic review, which account for a total of 316 patients. The results show a reduction of pro-inflammatory markers such as interleukins (IL) and tumor necrosis factor-alpha (TNF-α) through the intake of PUFA Ω -3 compared to placebo. It was also reported the formation of SPMs,which reduced the effects of inflammation in cardiovascular diseases. Based on the results obtained from this systematic review, a potential benefit can be obtained from the supplementation of PUFA Ω-3 for the resolution of vascular inflammation in cardiovascular diseases, by the reduction of inflammatory markers.